RxDoctor Payments Data

Sunil Malhotra, MD

Internal Medicine · Southaven, MSNPI 1841369907

Payments from drug & device makers

$646in general payments, 2019–2025

Across 21 payments — averaging $30.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$177
  • Alnylam Pharmaceuticals Inc.$151
  • Chiesi USA, Inc.$148
  • Philips North America LLC$79
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$34
  • Edwards Lifesciences$30
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$646100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$646 in reported general payments places this provider in the 55th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$523,324
Medicare patients
274
Services billed
2,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$125,149
IngrezzaValbenazine Tosylate24$89,342
MounjaroTirzepatide47$70,156
TrulicityDulaglutide40$66,234
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$34,099
OzempicSemaglutide28$31,857
XareltoRivaroxaban64$29,540
EntrestoSacubitril/Valsartan55$29,466
XifaxanRifaximin19$28,740
FarxigaDapagliflozin Propanediol32$18,776
RexultiBrexpiprazole15$16,136
JardianceEmpagliflozin40$15,593
MyrbetriqMirabegron19$7,537
Mirtazapine192$6,499
Atorvastatin Calcium420$6,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$125,149197 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$34$28,74019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Southaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →